Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murepavadin (POL7080) in VAP due to Pseudomonas aeruginosa
NCT02096328Phase 2Completed
- Sponsor
- Polyphor
- Start
- Oct 2013
- Primary completion
- Dec 2015
- Modality
- Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of murepavadin in ventilator-associated pneumonia (VAP), sponsored by Polyphor. Started Oct 2013; status: completed.
02
Drugs
murepavadin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02096328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096328.